STAA · STAAR Surgical Company

The thesis

STAAR Surgical's shares have recovered to $24.61 (adjusted close, 28 October 2026) ahead of the third-quarter report, but the China recovery is still unproven; the results and earnings call on 4 November 2026 settle it. The company has not issued a preliminary third-quarter sales release that a 28 October 2026 search of company filings and wire coverage could find, so the full report is the first hard number on how far China fell from the second quarter's $52.3 million.

The narrative is maturing: the $50 million buyback (24 September 2026) and the Stifel upgrade (29 September 2026) are well known, and the only company item since is the 21 October 2026 notice that the third-quarter call is set for 4 November 2026. The shares closed 26.2% below the 52-week high of $33.34 and 1.0% higher than three months earlier. Revenue has to confirm the recovery. The third quarter laps a one-time $25.9 million China order booked in the third quarter of 2025.

Bullish and bearish views on STAAR Surgical Company

The bull case on STAAR Surgical Company (STAA), in brief: Board authorised a $50 million buyback. The bear case: Management flagged a seasonal step-down.

Bull case

• Board authorised a $50 million buyback. On 24 September 2026 STAAR announced a repurchase program of up to $50 million over twelve months, funded from cash and free cash flow, per the company's announcement as reported by MarketBeat. The shares rose 6.3% that day, per Investing.com.

• Stifel upgraded to Buy. On 29 September 2026 Stifel raised its rating from Hold and lifted its price target to $31 from $28, citing China growth and adoption of the higher-priced EVO+ lens, per Investing.com.
• China drove the second-quarter recovery. The 12 August 2026 release reported China revenue of $52.3 million, up over 100% year over year and 10% from the first quarter, with net income of $8.1 million and a gross margin of 74.5%. Management said EVO+ supply constraints should ease by the end of the third quarter.
• Management expects growth against the adjusted comparison. In the 12 August 2026 release the company said that, excluding the one-time $25.9 million order, it anticipates strong third-quarter growth against an adjusted year-earlier figure of $68.8 million.

Bear case

• Management flagged a seasonal step-down. On the 12 August 2026 call the company said third-quarter China revenue should be moderately lower than the second quarter's $52.3 million. The size of that drop is the open question.
• Growth outside China is slow. Second-quarter ex-China revenue was $41.2 million, up 6.0%, per the 12 August 2026 release. A third quarter with no improvement leaves the recovery resting on one region.
• Reported revenue below that figure would show as a year-over-year decline.
• Analyst views diverge. Argus lowered its target to $21.00 on 16 September 2026 and UBS cut its target to $19 from $20 on 13 August 2026, per Benzinga. Stifel's $31 target sits well above the $24.61 close.
• Revenue is one product family. Sales come almost entirely from the EVO/EVO+ implantable lens, and the company gives no numeric revenue guidance.

Price setup

The adjusted close on 28 October 2026 was $24.61. That is above the 18 September 2026 close of $20.82, the low that preceded the buyback and the Stifel upgrade, and 26.2% below the 52-week high of $33.34. The 14-day relative strength index (a 0–100 momentum gauge) was 63.8, the high end of the neutral range.

The shares moved up from the $22.26 close of 15 October 2026 without any new company financial disclosure in that window. The rise priced in some expectation of a benign third-quarter print before the number is out. A third-quarter report that confirms only a moderate China step-down would meet that expectation; a sharper drop would test the $20.82 September low.

Crowding evidence is limited. Earnings fall within seven days of the last close. Broadwood Partners holds about 31% of the shares with board seats under the 15 January 2026 cooperation agreement, so the free float is small and moves can overshoot. No SEC Form 4 insider sales or share issuance appear in company filings since the prior note.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• 4 November 2026 — Third-quarter 2026 results and earnings call. The company announced the call date on 21 October 2026. It shows China sales against $52.3 million, ex-China growth against 6.0%, distributor inventory, and total net sales against the $94.7 million year-earlier figure. (passed 2d ago)
• Ongoing through 2027-09 — buyback execution. The $50 million program runs twelve months from 24 September 2026; the third-quarter filing shows whether repurchases have started. (passed 43d ago)
• Unscheduled — Alcon. Alcon's $30.75-per-share bid was voted down on 6 January 2026 and the standstill expired on 18 June 2026. No renewed approach has been announced. (passed 141d ago)

What would change the view

The case breaks if the third-quarter report shows China revenue falling sharply from $52.3 million, a distributor inventory build above management's target range, or ex-China growth at or below the 6.0% of the second quarter. Third-quarter net sales below the $94.7 million of a year earlier would add a headline decline to that.

On price, a daily close below $20.50 would put the shares under the 18 September 2026 close of $20.82 and erase the move that followed the buyback and the Stifel upgrade. Conversely, a report showing ex-China growth clearly above 6.0% with a moderate China decline would strengthen the case.

What it trades with

STAAR trades on its own China and ophthalmic-lens demand more than on a sector basket. Control by Broadwood and the small float add idiosyncratic moves around news, including any renewed takeover interest.